Navigation Links
FDA Requires Additional Information on DORIBAX for Treatment of Hospital-Acquired Pneumonia
Date:8/21/2008

RARITAN, N.J., Aug. 21 /PRNewswire/ -- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) today announced that the U.S. Food and Drug Administration (FDA) requires additional information before it will approve the company's New Drug Application (NDA) for DORIBAX(TM) (doripenem for injection) for the treatment of hospital-acquired pneumonia, also known as nosocomial pneumonia (NP), including ventilator-associated pneumonia (VAP).

In response to the J&JPRD application seeking approval for DORIBAX for the additional indication of the treatment of NP, including VAP, the FDA issued a Complete Response letter outlining the actions necessary to address outstanding issues.

J&JPRD is reviewing the agency's letter and will work to resolve any outstanding questions. The NDA for DORIBAX for the treatment of NP, including VAP, was submitted to the FDA in June 2007.

The NDA for DORIBAX for the treatment of NP, including VAP, was the subject of a July 16, 2008 U.S. Food and Drug Administration Anti-Infective Drugs Advisory Committee. Based on data presented from two large nosocomial pneumonia trials, the committee voted that 500 mg of DORIBAX at both the one-hour and four-hour infusion regimens were safe (8-5) and effective (7-6) in the treatment of NP, including VAP. The committee did not agree that the non-inferiority margin for the DORIBAX NP trials was appropriately justified, nor did it agree on the appropriate margin for NP trials in general. J&JPRD is confident in the NP data submitted and will work with the FDA to address the issues raised in the Complete Response letter.

DORIBAX is an intravenous (IV) antibiotic for hospital use, and belongs to a class of antibacterial drugs called carbapenems. Carbapenems are important antibiotics to treat serious -- and sometimes life-threatening -- infections caused by a broad range of bacteria, which are characterized as Gram-negative and Gram-positive, based on a classification
'/>"/>

SOURCE Johnson & Johnson Pharmaceutical Research & Development,L.L.C.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. ESBATech Raises Additional CHF 23M (USD 22M), Extending Series B Venture Financing
2. Biodel Inc. Announces the Completion of Its Two Pivotal Trials and the Release of EASD Abstracts Containing Additional Interim Data From Its VIAject(TM) Program
3. AlphaDetail AlphaPulse(TM): Most Practicing Physicians React Positively to FDA Panels Recommendation for Additional Cardiovascular Safety Trials for New Diabetes Medications.
4. Journal of Antimicrobial Chemotherapy Paper Supports Additional Role for Cethromycin as Potential Treatment for Infections Caused by Community- Associated Methicillin Resistant Staphylococcus Aureus (CA-MRSA)
5. Ardea Biosciences Reports Additional Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating Up to 1.9 Log Reduction in Plasma Viral Load with Once-Daily Dosing
6. PTC Therapeutics Announces Data from Additional Clinical Studies of PTC124 in Cystic Fibrosis Confirming Activity
7. Genaera Corporation Presents Additional Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at American Diabetes Association
8. BioElectronics Announces Profitability Breakeven and Additional Clinical Trials
9. QRxPharma Releases Additional Phase 3 Data for Q8003IR Dual Opioid Pain Therapy
10. Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
11. Go Healthy Initiates Additional Clinical Tests on Cholesterade
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... 30, 2015 Research ... of the "Deciphering Global Major Pharmaceutical Companies, ... their offering. It has been publicly ... involved in a series of challenges in the ... in significant overcapacities in small molecule product manufacturing; ...
(Date:7/7/2015)...   Decision Resources Group finds that ... management in the U.S. versus the EU5. In ... EU5 nephrologists from approximately 1,870 dialysis patient charts ... commonly used renal medications in dialysis patients; however, ... the two regions.      Other key findings ...
(Date:7/7/2015)... California and BANGALORE , ... , a global technology provider of innovative clinical trial ... Reports, (Industry Standard Research Reports) recent publication named " ... Provider Performance (2015) ". ISR Reports is one of ... pharmaceutical industry, and this report evaluated 22 EDC and ...
Breaking Medicine Technology:Deciphering Global Major Pharmaceutical Companies - New Outsourcing Demands and Strategies 2Deciphering Global Major Pharmaceutical Companies - New Outsourcing Demands and Strategies 3Similarities And Differences Exist When Comparing U.S. Versus EU5 Dialysis Patient Management 2Similarities And Differences Exist When Comparing U.S. Versus EU5 Dialysis Patient Management 3Acceliant Ranked Highest in 'Overall Satisfaction' Amongst EDC Providers in ISR Reports' Recent Research 2Acceliant Ranked Highest in 'Overall Satisfaction' Amongst EDC Providers in ISR Reports' Recent Research 3
... Cargill today announced encouraging preliminary results from its ... head of beef cattle.  Initial results are based upon ... company,s Fort Morgan, Colo., beef processing facility where vaccinated ... Addressing the food and feed safety ...
... Nov. 15, 2010 Breathe Technologies, manufacturer of devices ... has appointed Lawrence A. Mastrovich as the new President ... us a phenomenal wealth of experience and strategic guidance," ... visible and instrumental role in building value within the ...
Cached Medicine Technology:Cargill Encouraged by Preliminary Results From Beef Cattle Vaccine Trial 2Cargill Encouraged by Preliminary Results From Beef Cattle Vaccine Trial 3Breathe Technologies Appoints New CEO 2
(Date:7/7/2015)... ... ... Law Group is pleased to announce the relocation of the firm's headquarters to 225 ... a state of the art building, located with easy access to New York City's ... "We are pleased to service our clients from such a premier location and we ...
(Date:7/7/2015)... (PRWEB) , ... July 07, 2015 , ... SC&H Group, ... Service, which aims to give back to the community through company-wide volunteering efforts. , ... SC&H Group dedicate the day to assisting those in need throughout Baltimore and Washington ...
(Date:7/7/2015)... ... , ... At the end of June Pacific Prime Renewals team in Hong Kong announced ... by the Renewals Manager, Danielle Cotton, aims to not only reduce but eventually eliminate the ... explained, “We send anything between 300 and 600 pieces of paper per month. Not to ...
(Date:7/7/2015)... ... 07, 2015 , ... Summer is a great time to get outside and ... sharing some safety tips. , Jean Tapley, senior wellness coordinator at Amica, suggests the ... , Start slowly. Going from no activity to several hours of activity ...
(Date:7/7/2015)... ... ... Healthpointe is proud to announce the addition of Dr. Pedro S. Alupay to ... evaluating and treating patients with orthopedic complaints, such as lumbar back pain or cervical ... Biology from the University of the East, Manila, Dr. Alupay earned his Doctorate of ...
Breaking Medicine News(10 mins):Health News:SC&H Group Celebrates 9th Annual Day of Service 2Health News:Pacific Prime Hong Kong Renewals Team Starts Push to go Green 2Health News:Amica Insurance Has 7 Summer Safety Tips 2Health News:Dr. Pedro S. Alupay, M.D., Now Providing Pain Management Services at Healthpointe in Irwindale 2Health News:Dr. Pedro S. Alupay, M.D., Now Providing Pain Management Services at Healthpointe in Irwindale 3
... ... obscure Georgia Law that forces insurance companies to cover Sedation Dentistry for Georgia Dental Patients ... over 20 years and he just found out about the law so the general public ... ...
... SIAL ) today announced that it has entered into an agreement with Pfizer under which Sigma-Aldrich will sell approximately 100 Pfizer-developed small molecule ... ... , , ... ...
... ... a company that builds open source platforms and develops advanced research ... Health (NIH) totaling more than $600,000 to focus research efforts on ... the research is to work towards an interactive simulator that replicates ...
... The presence of plaque on an abdominal CT scan is ... to a Henry Ford Hospital study. Researchers found that ... artery disease when the CT scan showed very high levels ... of the abdominal aortic calcium also increased their risk of ...
... Diovan, Starlix also had limited or no effect in ... March 14 (HealthDay News) -- Hopes that two available ... causes in overweight people with poor sugar metabolism have ... trial involved two drugs prescribed for other reasons -- ...
... ... named to the editorial board of Otology/Neurotology. , ... (Vocus) March 13, 2010 -- Jed ... editorial board of Otology/Neurotology. The official journal of the American Otological Society and ...
Cached Medicine News:Health News:Georgia Dentist Uncovers Obscure Law That Helps Dental Patients With Severe Anxiety 2Health News:Sigma-Aldrich Reaches Agreement to Sell Pfizer's Bioactive Small Molecule Compounds 2Health News:Sigma-Aldrich Reaches Agreement to Sell Pfizer's Bioactive Small Molecule Compounds 3Health News:Sigma-Aldrich Reaches Agreement to Sell Pfizer's Bioactive Small Molecule Compounds 4Health News:Sigma-Aldrich Reaches Agreement to Sell Pfizer's Bioactive Small Molecule Compounds 5Health News:National Institutes of Health Awards Kitware Over $600,000 to Develop Advancements in Neurosurgical Simulation 2Health News:National Institutes of Health Awards Kitware Over $600,000 to Develop Advancements in Neurosurgical Simulation 3Health News:Plaque on CT scan is strong predictor of heart disease, worse long-term outcomes 2Health News:2 Drugs Fail to Prevent Diabetes in the Overweight 2Health News:2 Drugs Fail to Prevent Diabetes in the Overweight 3Health News:Summit Medical Group Physician Named to Medical Journal Editorial Board 2Health News:Summit Medical Group Physician Named to Medical Journal Editorial Board 3
... Direct has been selling replacement ... 1996, and we are extremely ... guarantee. Check out our catalog ... our discount light bulbs specials. ...
... Bulb Direct has been ... Internet since 1996, and we ... 100% satisfaction guarantee. Check out ... and see our discount light ...
... Direct has been selling replacement ... 1996, and we are extremely ... guarantee. Check out our catalog ... our discount light bulbs specials. ...
... Bulb Direct has been selling ... since 1996, and we are ... satisfaction guarantee. Check out our ... see our discount light bulbs ...
Medicine Products: